Excluding non-GAAP adjustments such as the amortization of obtained intangible assets and non-recurring charges, operating expenses were $48.5 million, in comparison to an altered total of $41.5 million in 2011. The boost reflects the acquisition of eBioscience in June 2012. Please refer to the Itemized Reconciliation Between GAAP and Non-GAAP Operating Expenses for a reconciliation of these GAAP and non-GAAP monetary measures. Results for the year ended December 31, 2012: Total income was $295.6 million, which excluding eBioscience of $37.0 million, represented a 3 percent decrease from 2011. GAAP net reduction was $10.7 million, or $0.15 per diluted share, when compared with a net lack of $28.2 million, or $0.40 per diluted share, in 2011.Lymphocytosis occurred concomitantly with a significant decrease in lymph-node size and spleen size, and also regular improvement in cytopenias . An improved response was time-dependent ; more and more partial responses and complete responses occurred during follow-up, whereas the regularity of a partial response with lymphocytosis diminished as the lymphocyte count reduced over time. As shown in Physique 2Shape 2Overall Response Rates According to Subgroup., the response to ibrutinib didn’t appear to vary according to traditional high-risk prognostic features. The response rate among the patients with a 17p13.1 deletion was 68 percent, including one complete response, whereas the response rate was 71 percent among those without this deletion.